Next Generation Orphan Drug Incentives

4:30 PM - 5:25 PM (PDT), Monday, June 8, 2020
Search General Info
Search Education
Search Partnering Companies
The promise of gene and cell therapies, advances in genetic screening and related diagnostics, and precision medicine has generated widespread enthusiasm throughout the rare disease community. At the same time, new patient-focused drug development is giving patient groups a pathway to new treatments. Yet, despite advances, 95% of rare diseases still do not have a treatment.

With Congress considering ways to update the 21st Century Cures Act and new studies imagining future scenarios, this session will explore new approaches to incentives and patient collaboration to foster a new era in orphan drug development for the 30 million Americans suffering with a rare disease.
Sponsored By
Moderator
photo
Chief Strategy Officer
Genetic Alliance
Speakers
photo
Chief Strategy Officer
Genetic Alliance
photo
Chief Financial Officer
Retrophin
photo
President & CEO
bluebird bio
photo
Founder & Director
IGA Nephropathy Foundation of America
photo
Chair, FDA Regulatory Practice
Lowenstein Sandler Pc